Aug 6, 2026 08:34AM
Jul 30, 2026 08:30AM
Jul 30, 2026 08:30AM
Jul 15, 2026 07:36AM
Jul 15, 2026 07:23AM
Jul 15, 2026 07:22AM
Jul 14, 2026 04:53PM FDA approves Celcuity's gedatolisib for a breast cancer subtype
Jul 14, 2026 04:53PM
Jun 3, 2026 10:13PM
Jun 3, 2026 10:13PM
Jun 3, 2026 07:19AM
Jun 3, 2026 07:19AM
Jun 2, 2026 08:26AM
Jun 2, 2026 08:25AM Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal
Jun 2, 2026 08:11AM
May 18, 2026 07:05AM
May 14, 2026 04:01PM
May 14, 2026 07:30AM
May 14, 2026 07:30AM
May 1, 2026 05:03PM
May 1, 2026 05:03PM Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Mar 25, 2026 04:01PM
Mar 9, 2026 05:42PM
Mar 9, 2026 05:42PM
Feb 12, 2026 04:05PM
Feb 12, 2026 04:05PM
Jan 20, 2026 07:30AM
Jan 20, 2026 07:30AM Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
Jan 8, 2026 12:08PM
Dec 11, 2025 02:35PM
Dec 11, 2025 02:35PM
Nov 17, 2025 04:05PM
Nov 12, 2025 04:01PM
Oct 18, 2025 04:30AM
Oct 18, 2025 04:30AM Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/
Sep 9, 2025 04:01PM
Sep 9, 2025 04:01PM
Aug 27, 2025 04:05PM
Aug 18, 2025 06:47AM
Aug 14, 2025 04:01PM
Jul 28, 2025 07:00AM
Jul 28, 2025 07:00AM Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial 
Dec 11, 2024 07:05AM
Dec 11, 2024 07:05AM
May 30, 2024 02:29PM
May 30, 2024 07:05AM
May 30, 2024 07:00AM
Nov 13, 2023 07:05AM
Aug 22, 2023 04:01PM Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer
Mar 23, 2023 04:00PM

328,453 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All